Breast cancer and ATM mutations: treatment implications

Area of Science:

• Oncology
• Genetics
• Cancer Predisposition

Background:

• Genetic testing for breast cancer has expanded to include panels with over 20 genes.
• Current recommendations advise offering extended gene panel testing to women diagnosed with breast cancer at age 65 or younger.

Purpose of the Study:

• To discuss the implications of extended genetic testing, particularly for genes like ATM, in breast cancer management.
• To highlight the need for further research into optimizing treatment and follow-up for women with ATM mutations.

Main Methods:

• Review of current recommendations and understanding of ATM gene mutations in breast cancer.
• Discussion of lifetime risks and cancer types associated with ATM mutations.

Main Results:

• ATM mutations confer a 25% lifetime breast cancer risk, predominantly ER-positive, and a 5% ovarian cancer risk.
• Current management and follow-up for breast cancer patients with ATM mutations are not distinct from those without mutations.

Conclusions:

• The clinical management implications of ATM mutations in breast cancer are not yet clearly defined.
• Large prospective studies are necessary to determine optimal treatment modalities for breast cancer patients with ATM mutations.